Multiplexed flow cytometric analyses of pro‐ and anti‐inflammatory cytokines in the culture media of oxysterol‐treated human monocytic cells and in the sera of atherosclerotic patients

C. Prunet1, Thomas Montange1, Anne Véjux1, Aline Laubriet2, Jean‐François Rohmer3, Jean‐Marc Riedinger4, Anne Athias1, Stéphanie Lemaire‐Ewing1, Dominique Néel1, Jean‐Michel Petit5, Éric Steinmetz2, R Brenot2, Philippe Gambert1, Gérard Lizard1
1Inserm U498/IFR 100, CHU/Hôpital du Bocage, Laboratoire de Biochimie Médicale, Dijon, France
2Service de Chirurgie Cardiovasculaire, CHU/Hôpital du Bocage, Dijon, France
3Centre d'Examens de Santé de la Caisse Primaire d'Assurance Maladie de Côte d'Or, Dijon, France
4Centre Anti‐Cancer GF Leclerc, Laboratoire de Biologie Médicale, Dijon, France
5Service d'Endocrinologie, CHU/Hôpital du Bocage, Dijon, France

Tóm tắt

AbstractBackground:

Some oxysterols are identified in atheromatous plaques and in plasma of atherosclerotic patients. We asked whether they might modulate cytokine secretion on human monocytic cells. In healthy and atherosclerotic subjects, we also investigated the relationships between circulating levels of C‐reactive protein (CRP), conventional markers of hyperlipidemia, some oxysterols (7β‐hydroxycholesterol, 7‐ketocholesterol, and 25‐hydroxycholesterol), and various cytokines.

Methods:

Different flow cytometric bead‐based assays were used to quantify some cytokines (IL‐1β, IL‐2, IL‐4, IL‐5, IL‐6, IL‐7, IL‐8, IL‐10, IL‐12, IL‐13, IL‐17, G‐CSF, GM‐CSF, IFN‐γ, MCP‐1, MIP‐1β, or TNF‐α) in the culture media of oxysterol‐treated U937 and THP‐1 cells, and in the sera of healthy and atherosclerotic subjects. CRP and markers of hyperlipidemia were determined with routine analytical methods. Oxysterols were quantified by gas chromatography/mass spectrometry. Flow cytometric and biochemical methods were used to measure IL‐8 mRNA levels, intracellular IL‐8 content, and protein phosphorylation in the mitogenic extracellular kinase/extracellular signal‐regulated kinase1/2 (MEK/ERK1/2) signaling pathway.

Results:

All oxysterols investigated are potent in vitro inducers of MCP‐1, MIP‐1β, TNF‐α, and/or IL‐8 secretion, the latter involving the MEK/ERK1/2 cell signaling pathway. In healthy and atherosclerotic subjects, no relationships were found between cytokines (IL‐8, IL‐1β, IL‐6, IL‐10, TNF‐α, IL‐12, and MCP‐1), CRP, conventional markers of hyperlipidemia, and oxysterols. However, in patients with arterial disorders of the lower limbs, small but statistically significant differences in the circulating levels of CRP, TNF‐α, and IL‐10 were observed comparatively to healthy subjects and according to the atherosclerotic stage considered.

Conclusions:

Flow cytometric bead‐based assays are well adapted to measure variations of cytokine secretion in the culture media of oxysterol‐treated cells and in the sera of healthy and atherosclerotic subjects. They underline the in vitro proinflammatory properties of oxysterols and may permit to distinguish healthy and atherosclerotic subjects, as well as various atherosclerotic stages. © 2006 International Society for Analytical Cytology

Từ khóa


Tài liệu tham khảo

Strong JP, 1992, Atherosclerotic lesions. Natural history, risk factors, and topography, Arch Pathol Lab Med, 116, 1268

10.1038/35025203

10.1146/annurev.bi.52.070183.001255

10.1161/01.ATV.18.3.423

10.1038/nm1102-1235

10.1161/01.CIR.92.5.1355

10.1007/BF01660974

10.1056/NEJM199901143400207

10.1161/01.CIR.0000052939.59093.45

10.1097/00041433-199810000-00003

10.1023/B:THRO.0000036027.39353.70

10.1161/01.CIR.99.3.420

10.1161/atvb.21.9.1389

10.1038/nature01323

10.1016/S0021-9150(98)00196-8

10.1161/01.ATV.19.4.967

10.1080/10715760100300431

10.1016/S0014-5793(98)01496-3

10.1161/01.ATV.17.2.317

10.1016/S0014-5793(97)01473-7

10.1161/01.ATV.19.3.611

10.1016/S1568-9972(01)00003-9

10.1006/bbrc.1998.9385

10.1111/j.1749-6632.2002.tb04627.x

10.1016/S0014-4835(03)00029-0

10.1002/(SICI)1096-9896(199711)183:3<330::AID-PATH933>3.0.CO;2-7

10.1128/MCB.24.24.10703-10717.2004

10.1016/0021-9150(95)05594-M

10.1074/jbc.271.15.8837

10.1023/A:1010914306375

10.1038/sj.cdd.4401434

10.1023/B:THRO.0000037664.77460.d8

10.1161/hq1201.100220

10.1023/A:1011006707414

10.1016/j.tcm.2004.02.006

10.1016/S0001-4079(19)34077-4

10.1096/fasebj.12.15.1651

10.1016/S0022-1759(00)00238-6

10.1016/S0301-472X(02)00922-0

10.1016/S0022-1759(01)00407-0

10.1046/j.1365-2222.1998.00312.x

10.1007/s10565-005-0141-2

10.1016/0022-1759(81)90174-5

10.1038/sj.cdd.4400792

10.1002/cyto.990210308

Friedewald WT, 1972, Estimation of the concentration of low density lipoprotein cholesterol in plasma, without the use of preparative ultracentrifuge, Clin Chem, 18, 499, 10.1093/clinchem/18.6.499

10.1016/S0022-2275(20)38634-X

10.1006/abio.1995.1110

10.1161/01.CIR.95.4.840

10.1016/S0021-9150(96)06022-4

10.1074/jbc.270.46.27489

10.1097/00041433-200110000-00009

Aikawa M, 2004, Atherosclerotic plaque inflammation: The final frontier?, Can J Cardiol, 20, 631

10.5551/jat.11.313

10.1007/s00395-005-0511-6

10.1056/NEJMoa032804

10.1016/S0021-9150(99)00343-3

10.1016/S0003-2697(02)00467-0

10.1016/S1568-9972(02)00059-9

10.1097/00041433-200310000-00002

10.1016/S0021-9150(02)00301-5

10.1097/00001573-200307000-00001

10.1161/01.CIR.100.1.96

10.1016/j.freeradbiomed.2005.06.024

10.5551/jat1994.1.Supplemment1_S10

10.1080/07853890310019961

10.1074/jbc.272.45.28568

10.1016/S0021-9150(00)00380-4

10.1016/S1567-5769(01)00113-8

10.1074/jbc.M501759200

10.1056/NEJMoa021993

10.1002/cyto.b.20021